Skip to main content
Erschienen in: Supportive Care in Cancer 6/2014

01.06.2014 | Original Article

Awareness, concern, and communication between physicians and patients on bone health in cancer

verfasst von: Debu Tripathy, Brian G. M. Durie, Beatrice Mautner, Krag S. Ferenz, Judd W. Moul

Erschienen in: Supportive Care in Cancer | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study aims to explore physician–patient communications about bone metastases and cancer treatment-induced bone loss (CTIBL).

Methods

The study utilizes online survey of patients with breast cancer, prostate cancer, and multiple myeloma, and the physicians who treat them.

Results

Even though 69 and 48 % of patients with nonmetastatic breast and prostate cancer aware of treatment-induced bone loss, only 39 and 23 %, respectively, were concerned about bone loss. Yet, 62 and 71 % of oncologists treating breast and prostate cancer felt that their patients were concerned. Among patients with metastatic breast and prostate cancer, two thirds had not discussed treatment for bone metastases with their doctor; when discussed, 88 and 91 % of discussions were initiated by the doctor, usually prior to initiating treatment. Most myeloma patients (77 %) had discussed treatment options with their physicians; 99 % of hematologists reported discussing treatment of bone disease with patients.

Conclusions

Physicians are primary sources of information to patients regarding bone health. There is a gap between what physicians assume their patients know about bone health and the patients’ perceptions, presenting a need for systematic awareness and education.
Literatur
1.
Zurück zum Zitat Body J-J (2010) Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol 21:vii180–vii185PubMedCrossRef Body J-J (2010) Prevention and treatment of side-effects of systemic treatment: bone loss. Ann Oncol 21:vii180–vii185PubMedCrossRef
2.
Zurück zum Zitat Vanderwalde A, Hurria A (2011) Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 61:139–156PubMedCrossRef Vanderwalde A, Hurria A (2011) Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 61:139–156PubMedCrossRef
3.
Zurück zum Zitat Pfeilschifter J, DielI J (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570–1593PubMed Pfeilschifter J, DielI J (2000) Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 18:1570–1593PubMed
4.
Zurück zum Zitat Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sPubMedCrossRef Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12:6243s–6249sPubMedCrossRef
5.
Zurück zum Zitat Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–1090PubMedCrossRef Lipton A, Theriault RL, Hortobagyi GN et al (2000) Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 88:1082–1090PubMedCrossRef
6.
Zurück zum Zitat Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRef Saad F, Gleason DM, Murray R et al (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRef
7.
Zurück zum Zitat Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164 Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352:154–164
8.
Zurück zum Zitat Oster G, Lamerato L, Glass AG et al (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 21(12):3279–3286, 2013 DecPubMedCrossRef Oster G, Lamerato L, Glass AG et al (2013) Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer 21(12):3279–3286, 2013 DecPubMedCrossRef
9.
Zurück zum Zitat Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30 Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63:11–30
10.
Zurück zum Zitat National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: multiple myeloma, version 1. 2012. www.nccn.org. Accessed 25 March 2012 National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: multiple myeloma, version 1. 2012. www.​nccn.​org. Accessed 25 March 2012
11.
Zurück zum Zitat Berenson JR, Lichtenstein A, Porter L et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593–602PubMed Berenson JR, Lichtenstein A, Porter L et al (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593–602PubMed
12.
Zurück zum Zitat National Comprehensive Cancer Network (2012) Clinical Practice guidelines in oncology: breast cancer, version 1. 2012. www.nccn.org. Accessed 25 March 2012 National Comprehensive Cancer Network (2012) Clinical Practice guidelines in oncology: breast cancer, version 1. 2012. www.​nccn.​org. Accessed 25 March 2012
13.
Zurück zum Zitat National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: prostate cancer, version 1. 2012. www.nccn.org. Accessed 25 March 2012 National Comprehensive Cancer Network (2012) Clinical practice guidelines in oncology: prostate cancer, version 1. 2012. www.​nccn.​org. Accessed 25 March 2012
14.
Zurück zum Zitat Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057PubMedCrossRef Hillner BE, Ingle JN, Chlebowski RT et al (2003) American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042–4057PubMedCrossRef
15.
Zurück zum Zitat Cummings SR, Bates D, Black DM (2002) Clinical use of bone densitometry: scientific review. JAMA 288:1889–1897PubMedCrossRef Cummings SR, Bates D, Black DM (2002) Clinical use of bone densitometry: scientific review. JAMA 288:1889–1897PubMedCrossRef
16.
Zurück zum Zitat Gralow JR, Biermann JS, Farooki A et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7:S1–S32 Gralow JR, Biermann JS, Farooki A et al (2009) NCCN task force report: bone health in cancer care. J Natl Compr Cancer Netw 7:S1–S32
17.
Zurück zum Zitat Muusses LD, Weert JCM, Dulmen S, Jansen J (2012) Chemotherapy and information-seeking behaviour: characteristics of patients using mass-media information sources. Psychooncology 21:993–1002PubMedCrossRef Muusses LD, Weert JCM, Dulmen S, Jansen J (2012) Chemotherapy and information-seeking behaviour: characteristics of patients using mass-media information sources. Psychooncology 21:993–1002PubMedCrossRef
18.
Zurück zum Zitat Rutten LJL, Arora NK, Bakos AD, Aziz N, Rowland J (2005) Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Educ Couns 57:250–261PubMedCrossRef Rutten LJL, Arora NK, Bakos AD, Aziz N, Rowland J (2005) Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Educ Couns 57:250–261PubMedCrossRef
19.
Zurück zum Zitat McKean H, Looker S, Hartmann LC et al (2008) Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions. J Nutr Educ Behav 40:144–148PubMedCrossRef McKean H, Looker S, Hartmann LC et al (2008) Are cancer survivors/patients knowledgeable about osteoporosis? Results from a survey of 285 chemotherapy-treated cancer patients and their companions. J Nutr Educ Behav 40:144–148PubMedCrossRef
20.
Zurück zum Zitat Nagler RH, Gray SW, Romantan A et al (2010) Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Educ Couns 81:S54–S62PubMedCrossRef Nagler RH, Gray SW, Romantan A et al (2010) Differences in information seeking among breast, prostate, and colorectal cancer patients: results from a population-based survey. Patient Educ Couns 81:S54–S62PubMedCrossRef
21.
Zurück zum Zitat Lewis N, Gray SW, Freres DR, Hornik RC (2009) Examining cross-source engagement with cancer-related information and its impact on doctor-patient relations. Health Commun 24:723–734PubMedCentralPubMedCrossRef Lewis N, Gray SW, Freres DR, Hornik RC (2009) Examining cross-source engagement with cancer-related information and its impact on doctor-patient relations. Health Commun 24:723–734PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Davies NJ, Kinman G, Thomas RJ, Bailey T (2008) Information satisfaction in breast and prostate cancer patients: implications for quality of life. Psychooncology 17:1048–1052PubMedCrossRef Davies NJ, Kinman G, Thomas RJ, Bailey T (2008) Information satisfaction in breast and prostate cancer patients: implications for quality of life. Psychooncology 17:1048–1052PubMedCrossRef
23.
Zurück zum Zitat Martinez LS, Schwartz JS, Freres D, Fraze T, Hornik RC (2009) Patient–clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed. Patient Educ Couns 77(3):384–390PubMedCentralPubMedCrossRef Martinez LS, Schwartz JS, Freres D, Fraze T, Hornik RC (2009) Patient–clinician information engagement increases treatment decision satisfaction among cancer patients through feeling of being informed. Patient Educ Couns 77(3):384–390PubMedCentralPubMedCrossRef
Metadaten
Titel
Awareness, concern, and communication between physicians and patients on bone health in cancer
verfasst von
Debu Tripathy
Brian G. M. Durie
Beatrice Mautner
Krag S. Ferenz
Judd W. Moul
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 6/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2127-1

Weitere Artikel der Ausgabe 6/2014

Supportive Care in Cancer 6/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.